PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50325C00004BULK PHARMA - GROUP b (asset — Fresenius Kabi, LLC

Fresenius Kabi, LLC holds $98.3M across 1,575 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 2 related awards in the incumbent pipeline. Competition previously drew 5 offers. Set-aside status: NONE. Recompete timing centers on the Mar 13, 2030 PoP end — agencies typically plan 12–18 months ahead.

Aspr/Orm-Sns

Awarding office

Fresenius Kabi, LLC

Recipient

Mar 13, 2030

PoP end

$86.3M

Obligated

325412

NAICS

6505

PSC

NONE

Set-aside

5 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Fresenius Kabi, LLC — $90

Contract facts

NONE

Contract number75A50325C00004

AgencyAspr/Orm-Sns

Awarding officeAspr/Orm-Sns

IncumbentFresenius Kabi, LLC

UEIC2TRNWNQKMD6

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Place of performanceLAKE ZURICH, IL

PoP end (current)Mar 13, 2030

Obligated$86.3M

BULK PHARMA - GROUP B (ASSET MGMT) ACYCLOVIR SODIUM SOLUTION, DOXYCYCLINE INJ., MEROPENEM, SODIUM CHLORIDE, STERILE WAT… is a federal NONE award for Aspr/Orm-Sns held by Fresenius Kabi, LLC. Estimated value $86.3M ($86.3M obligated). Current period of performance ends Mar 13, 2030. Last award drew 5 bidders. Place of performance: LAKE ZURICH, IL.

BULK PHARMA - GROUP B (ASSET MGMT) ACYCLOVIR SODIUM SOLUTION, DOXYCYCLINE INJ., MEROPENEM, SODIUM CHLORIDE, STERILE WATER

Recompete timing

Public

● Expiring in 1283 days

Current PoP ends Mar 13, 2030 (1283 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Sep 13, 2028.

Incumbent footprint

Public record

Fresenius Kabi, LLC — $98.3M obligated across 1,575 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($98.3M) · all agencies

Department of Health and Human Services (HHS)$94.1M · 96%Department of Defense (DOD)$4.2M · 4%

Open full company profile →

Related awards

Same incumbent

75A50326F80006

ATROPINE 0.4MGML X 20ML SOLN. FOR INJ., MULTI-DOSE VIALS 8MG AND MIDAZOLAM SOLN. FOR INJ.,…

$7.9M

Jul 29, 2027

SPE2D025F0535

8511525788!OTHER MEDICAL

$1.4M

Aug 31, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50325C00004?

75A50325C00004 (BULK PHARMA - GROUP b (asset) is a Aspr/Orm-Sns award with an estimated value of $86.3M, currently held by Fresenius Kabi, LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50325C00004?

Aspr/Orm-Sns awarded 75A50325C00004 to Fresenius Kabi, LLC.

Who is the incumbent on 75A50325C00004?

Fresenius Kabi, LLC is the incumbent with $98.3M across 1575 related awards in SCOUT’s public footprint. The current period of performance ends Mar 13, 2030.

When does Fresenius Kabi, LLC’s 75A50325C00004 come up for recompete?

SCOUT tracks a period-of-performance end of Mar 13, 2030. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75A50325C00004 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action Sep 11, 2025